Literature DB >> 17653126

Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans.

Maria-Grazia Roncarolo1, Manuela Battaglia.   

Abstract

Substantial progress in understanding the biology of regulatory T cells and their roles in health and disease has been achieved in the past 10 years. This has led to an increasing interest in the possibility of using regulatory T cells as a biological therapy to preserve and restore tolerance to self antigens and alloantigens. Immunotherapy by the adoptive transfer of regulatory T cells may have several advantages over conventional treatments. However, several hurdles have to be overcome before such a therapy can enter clinical practice. This Review summarizes our current knowledge of regulatory T cells, illustrates the ongoing regulatory T-cell-based clinical trials, analyses the strengths and pitfalls of this new therapeutic approach, and highlights the future perspectives.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17653126     DOI: 10.1038/nri2138

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  186 in total

1.  Th17 cells express interleukin-10 receptor and are controlled by Foxp3⁻ and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner.

Authors:  Samuel Huber; Nicola Gagliani; Enric Esplugues; William O'Connor; Francis J Huber; Ashutosh Chaudhry; Masahito Kamanaka; Yasushi Kobayashi; Carmen J Booth; Alexander Y Rudensky; Maria Grazia Roncarolo; Manuela Battaglia; Richard A Flavell
Journal:  Immunity       Date:  2011-04-22       Impact factor: 31.745

2.  Oligodeoxynucleotides stabilize Helios-expressing Foxp3+ human T regulatory cells during in vitro expansion.

Authors:  Yong Chan Kim; Ravikiran Bhairavabhotla; Jeongheon Yoon; Amit Golding; Angela M Thornton; Dat Q Tran; Ethan M Shevach
Journal:  Blood       Date:  2012-01-31       Impact factor: 22.113

Review 3.  Historical overview of immunological tolerance.

Authors:  Ronald H Schwartz
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-04-01       Impact factor: 10.005

4.  Segregated regulatory CD39+CD4+ T cell function: TGF-β-producing Foxp3- and IL-10-producing Foxp3+ cells are interdependent for protection against collagen-induced arthritis.

Authors:  Irina Kochetkova; Theresa Thornburg; Gayle Callis; David W Pascual
Journal:  J Immunol       Date:  2011-10-03       Impact factor: 5.422

5.  Tregs and human atherothrombotic diseases: toward a clinical application?

Authors:  Giuseppina Caligiuri; Antonino Nicoletti
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-09       Impact factor: 8.311

Review 6.  How tolerogenic dendritic cells induce regulatory T cells.

Authors:  Roberto A Maldonado; Ulrich H von Andrian
Journal:  Adv Immunol       Date:  2010       Impact factor: 3.543

7.  Regulatory T cells in renal disease.

Authors:  Yuan Min Wang; Min Hu; Ya Wang; Tania Polhill; Geoff Yu Zhang; Yiping Wang; Vincent W S Lee; David C H Harris; Stephen I Alexander
Journal:  Int J Clin Exp Med       Date:  2008-08-20

Review 8.  Beyond regulatory T cells: the potential role for IL-2 to deplete T-follicular helper cells and treat autoimmune diseases.

Authors:  André Ballesteros-Tato
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

9.  Mammalian target of rapamycin inhibition and alloantigen-specific regulatory T cells synergize to promote long-term graft survival in immunocompetent recipients.

Authors:  Giorgio Raimondi; Tina L Sumpter; Benjamin M Matta; Mahesh Pillai; Natasha Corbitt; Yoram Vodovotz; Zhiliang Wang; Angus W Thomson
Journal:  J Immunol       Date:  2009-12-09       Impact factor: 5.422

10.  Selective expression of latency-associated peptide (LAP) and IL-1 receptor type I/II (CD121a/CD121b) on activated human FOXP3+ regulatory T cells allows for their purification from expansion cultures.

Authors:  Dat Q Tran; John Andersson; Donna Hardwick; Lolita Bebris; Gabor G Illei; Ethan M Shevach
Journal:  Blood       Date:  2009-03-18       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.